Canaccord Genuity and Barclays Raise Kenvue (KVUE) Price Targets

Core Insights - Kenvue Inc. (NYSE:KVUE) is recognized as one of the 10 best stocks under $20 to buy according to hedge funds, with Barclays raising its price target from $18 to $19 while maintaining an Equalweight rating [1] - The company has shown strong performance in classic consumer health categories, particularly in Self Care and Essential Health, but needs to adopt a different strategy for its beauty segment focused on premiumization and innovation [2] - Canaccord Genuity also raised its price target for Kenvue from $17 to $18, maintaining a Hold rating, following the company's Q4 and full-year 2025 results [3] Financial Performance - Kenvue's Q4 sales increased by 3.2% year-over-year, surpassing the Street estimate of 0.4%, with organic sales rising by 1.2% compared to the same period last year [4] - All segments of Kenvue reported growth in Q4, and the adjusted EPS was $0.27, exceeding the Street estimate of $0.22 [4] - Kenvue is a global consumer health company with well-known brands including Aveeno, BAND-AID, Johnson's, Listerine, Neutrogena, and Tylenol [4]